Aktiesnakken — November 2009
-
Er ellers sevet jelt jævnt
-
så er vi igang med ALK
-
her for interesserede...
-
healthy earnings development..siges der
. -
jutta af rosenborg gennemgår resultaterne.....
-
capacity cost er op 1% i år......... heraf dog 6% stigning i q3
-
really challenging market in italy..... pga. economy.
-
good overall progress af grazax salget....
-
bl.a. pga. lancering af grazax til børn.
-
Balancen...... loans close to 0...... 366 mio i cash
-
fairly stort salg i september..... fører til negativ ændring i arbejdskapital per 30.sep
-
ebit på 150 mio for 2009.... inlc. 33mio ragweed fra schering plough
-
ebitda.. lille nedjustering syntes jeg at høre.... 230mio.
-
grazax trial udført af schering plough.. vil blive præsenteret i 2010 på en conference
-
SP og Merck fusion finalised d. 3. nov.
-
long term study af grazax.... results early 2010 som jeg hørte det.
-
grazax mod astma....i børn... trial er sat i gang.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind